摘要
目的评估不稳定型心绞痛（unstable angina,UA）患者住院应用丹参多酚酸盐对经皮冠状动脉介入治疗围术期的疗效。方法选择2015年1月～2016年2月在浙江中医药大学附属第二医院心内科治疗的UA患者96例,将96例UA患者随机均分为治疗组和对照组,各48例。两组均常规应用抗心肌缺血药物、β-受体阻滞剂、阿司匹林、氯吡格雷、他汀类药物、血管紧张素转换酶抑制剂（angiotensin converting enzyme inhibitors,ACEI）/血管紧张素Ⅱ受体拮抗剂（angiotensin receptor blocker,ARB）、低分子肝素,治疗组于PCI术前连用丹参多酚酸盐（200 mg/d）治疗3 d,术前术后共应用8 d。观察两组患者的临床疗效及围手术期低密度脂蛋白胆固醇LDL-C、hs-CRP、hs-cTnI、CK-MB、Hcy、D-二聚体、血黏度的变化,并随访3个月观察主要心脑血管事件以及药物不良反应。结果治疗组较对照组总有效率升高（95.83%vs 81.25%）（P〈0.05）。与对照组治疗后相比,治疗组治疗后hs-CRP、CK-MB、Hcy、D-二聚体、血黏度水平均较低,差异有统计学意义（P〈0.05）。随访3个月主要心脑血管事件发生率分别为4.17%与18.75%（P〈0.05）。结论丹参多酚酸盐注射液可改善不稳定型心绞痛患者临床疗效,不增加出血风险,具有良好的安全性和可行性。
Objective To review the perioperative effect of salvianolate injection in patients with unstable angina pectoris（UAP） during percutaneous coronary intervention（PCI） period. Methods From Jan 2015 to February 2016,a total of ninety-six patients were included in this study. Those patients with UA were randomly divided into the therapy group（salvianolate set）and the control group with forty-eight cases in each. Two groups were given routinely drugs such as anti-ischemic drug therapy, beta-blocker, aspirin, clopidogrel, statins, ACEI/ARB and low molecular heparin,while the therapy group was administered with salvianolate（200 mg/d） three days additionally. Therapy group was treated for 8 days in whole perioperative. The clinical efficacy, the levels and the changes of LDL-C,hs-CRP,hs-cTnI,CK-MB,Hcy,D-dimer and blood viscosity during perioperative were observed between the two groups. During the 3months follow-up, the occurrence of adverse major adverse cardiac or cerebral events and drug adverse reactions were compared between two groups. Results After the treatment,the total effective rates were 95.83% in the therapy group and 81.25% in the control group, with a significant difference（P〈0.05）. Compared with the control group the level of hs-CRP, hs-cTnI, CK-MB, Hcy, D-dimer and blood viscosity decreased obviously in the therapy group, with a significant difference（P〈0.05）. After three months of follow-up,the total incidence rates of cardiac or cerebral events were 4.17% in the therapy group and 18.75% in the control group, with a significant difference（P〈0.05）. Conclusion Peri-PCI salvianolate use is safe and effective related with low bleeding risk in patients with UA,and it can improve the clinical therapeutic effect.
出处
《中国现代医生》
2016年第21期99-103,共5页
China Modern Doctor
基金
基金项目:浙江省中医药(中西医结合)重点学科建设(2012-XK-A16)
关键词
丹参多酚酸盐
不稳定性心绞痛
PCI围术期
心肌保护
Salvianolate
Unstable angina
Perioperative percutaneous coronary intervention
Myocardial protection
